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The effects of serial casting on lower limb
function for children with Cerebral Palsy: a
systematic review with meta-analysis
Nikki Milne1,2* , Michelle Miao1 and Emma Beattie1
Abstract
Background: Lower limb serial casting is commonly used therapeutically in paediatric clinical practice with some
evidence to support its efficacy. This systematic review aimed to determine the effects of serial casting in isolation
or combination with other therapies for the management of lower limb dysfunction in children with Cerebral Palsy
(CP).
Methods: A systematic literature search was conducted in February 2019 across eight databases (PUBMED, EMBASE,
CINAHL, PEDro, OTSeeker, Cochrane, Scopus and Proquest) using key terms ‘Cerebral Palsy’ and ‘serial casting’ and
associated synonyms. A meta-synthesis and meta-analysis were undertaken when sufficient results were available
showing the effect of serial casting on functional outcomes including: Ankle range of motion; neurological
measures of hypertonicity and spasticity, functional gait measures and; gross motor function.
Results: Twenty-five articles from 3219 possible citations were included. Serial casting was found to be effective for:
Improving ankle dorsiflexion (DF) passive range of motion (PROM) in the immediate to short-term, decreasing
hypertonicity measured by Modified Ashworth Scale (MAS) in the short-term and, enhancing functional gait
outcomes in the mid-term. Serial casting with or without botulinum toxin type-A (BTX-A) did not significantly affect
gross motor capacity measured by Gross Motor Function Measure (GMFM). Serial casting with pharmacological
intervention achieved significantly more DF PROM than serial casting alone (MD − 3.19 degrees; 95% CI − 5.76 to −
0.62; P = 0.01; I2 = 0%), however the clinical importance of improving ankle DF PROM by an additional three degrees
remains unclear.
Conclusions: Lower limb serial casting, improves several outcomes relevant to lower limb function supporting its
clinical use for improving DF PROM, reducing hypertonicity and improving gait in children with CP. Further research
using stronger methodological study designs, is indicated to explore long-term effects of serial casting on
functional lower limb outcomes such as gross motor function in children with CP. Clinicians can use this
information when developing individualised treatment plans for children who have CP during shared decision-
making consultations.
Keywords: Cerebral palsy, Serial casting, Children, Lower limb, Function, Meta-synthesis, Meta-analysis, Ankle, Range,
Hypertonicity
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Background
Cerebral Palsy (CP) is classified as a group of postural
and motor disorders caused by a non-progressive lesion
to the developing brain, aquired before the age of two
[1, 2]. Affecting approximately 2.11 per 1000 live births
worldwide and slightly less in western countries (e.g.
Sweden with 1.96 per 1000 live births) [3], CP is a preva-
lent condition seen in the paediatric healthcare setting
[4]. The impact of CP on functional capacity varies
greatly as does the level of disruption to the developing
brain [5]. Due to its non-progressive nature, a focus of
rehabilitation by physiotherapists is managing associated
primary and secondary complications, such as spasticity
and contracture, which are often not present at the time
of the initial injury to the brain [6]. This focus is clinic-
ally reasoned to be an initial step towards improved mo-
bility, so that the focus of rehabilitation can progress
towards more functional activity and participation goals,
which are thought to be more meaningful activities to
individuals with CP for their daily living [7] .
Among the different types of CP, spastic CP is the
most common form consisting of approximately 85.8%
of diagnoses [8]. Spasticity of a muscle is defined as a
velocity-dependent resistance of a muscle to stretch [9]
impacting the range of motion around a particular joint
[10]. Without appropriate management, spasticity may
contribute to the onset of contractures of the muscles,
ligaments and tendons [11, 12], affecting loading bio-
mechanics and causing major functional limitations [13].
For example, contracture of the gastrocnemius-soleus
complex can cause equinus positioning of the foot,
which adversely affects standing balance and increases
energy expenditure during walking [14, 15]. Interven-
tions focused on improving posturing of the lower limb
would likely enhance gait kinematics and improve walk-
ing distance [14]. Many studies have identified the amp-
lified functional impact that contractures, specifically
contractures of the lower limb, have on ambulation and
a child’s ability to complete functional everyday tasks
[16, 17]. There is a clear need to identity the most ap-
propriate and effective intervention strategies to
minimize negative effects and maximize functional
outcomes.
Current clinical management of spasticity and contrac-
ture in the lower limb includes conservative approaches
such as the use of physiotherapy, orthoses, casting and
splinting [18]. Other commonly used invasive strategies
for spasticity and contracture management include
neurotoxin injections such as botulinum toxin A (BTX-
A) and intrathecal baclofen, as well as surgery such as
selective dorsal rhizotomy (SDR) and various corrective
orthopaedic operations [11, 17] including tendon length-
ening procedures and single-event multilevel surgeries
(SEMLS) [19, 20]. Previous studies have supported the
efficacy of interventions including BTX-A, diazepam and
SDR for the management of spasticity [17, 21–23]. How-
ever, some previous research findings suggest that sur-
gery for children with spasticity, if performed at a young
age, can yield undesirable and sometimes unpredictable
outcomes such as recurrent equinus, infection and over-
lengthening of muscle tendon units [22–24]. As a result,
non-surgical interventions have been suggested clinically
as temporising measures until the child is more
musculo-skeletally developed [23].
In the research literature, serial casting is commonly
referred to as the application of two or more successive
fibreglass or plaster casts to a particular joint with efforts
to increase passive range of motion (PROM) around a
joint by maintaining prolonged passive stretch in the
submaximal or maximal range [21, 25–27] which allows
more opportunity for active ROM (AROM). Submaximal
refers to the point between initial resistance to passive
stretch and the point at which no further stretch is pos-
sible and is determined by the clinician as well as patient
tolerance [28, 29].
A recent review of systematic reviews conducted by
Novak and colleagues [17] summarized the evidence of
various interventions for children with CP. Evidence was
found to support the use of lower limb casting to alter
body structures, however, only low-quality evidence was
reported to have a positive effect on improving activity
limitations as per the International Classification of
Functioning, Disability and Health (ICF) model [30]. In
relation to the lower limbs, increased physical activity
was the most common recommendation for targeting a
child’s ability to complete activities (e.g. walking) [17].
Several authors from studies cited in two previous sys-
tematic reviews [17, 25] recommended serial casting be
used to improve PROM at the ankle to enhance func-
tional outcomes in children with CP. However, because
serial casting is commonly used in combination with
BTX-A injections [21, 31] and other therapies [19], the
isolated effects of serial casting on the lower limb and in
particular short-leg walking casts have not yet been
clearly identified in the research literature [32], despite it
being a common therapeutic intervention in the man-
agement of children with CP [21]. In 2007, Blackmore
and colleagues published a systematic review reporting
on limited evidence, suggesting that serial casting is
more effective in the management of secondary compli-
cations of CP than no serial casting [21]. This previously
published evidence regarding the effects of serial casting
alone to influence lower limb function warrants further
investigation with recent additions to the empirical lit-
erature. Additionally, Blackmore et al. acknowledge that
many studies included in their review had insufficient
sample sizes, lacked randomization and lacked blinding,
making it difficult to identify the true effects of the
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interventions [21]. For this reason, it is important to en-
sure that conclusions regarding the effect of serial cast-
ing on the lower limb are based on studies with sound
methodological quality. More recently two systematic re-
views [32, 33] explored the empirical literature to deter-
mine the efficacy of using adjunct therapies to improve
outcomes after BTX-A injections in children with CP.
Whilst both systematic reviews are valuable contribu-
tions to the research literature, the aims and findings of
these reviews are impacted by the contribution of BTX-
A and do not set out to explore the effects of serial cast-
ing independent of pharmacological interventions such
as BTX-A.
Despite the conclusions of previously published sys-
tematic reviews, it is still unclear as to whether serial
casting is effective for improving lower limb function
(including the body function and structure and activity
level functions such as gait and gross motor proficiency)
in children with CP. This uncertainty is attributed to a
wide range of study designs, casting protocols, and com-
binations of additional therapies documented in the
current literature, making it difficult to isolate and deter-
mine the efficacy of serial casting as an intervention [17,
25] independent of pharmacological therapies. Consider-
ing recent contributions to the empirical literature re-
garding the potentially damaging effects of BTX-A to
gait in children with CP [34], the findings from this sys-
tematic review are warranted to assist clinicians, parents
and clients in shared decision-making processes. As
such, the purpose of this systematic review was to critic-
ally appraise and synthesize the empirical literature re-
garding the effects of serial casting, compared to serial
casting with pharmacological intervention, on the differ-
ent variables influencing function of the lower limbs, in
children with CP. In synthesizing the findings from
moderate to high quality studies, the authors of this re-
view aimed to:
1. Determine the effects of serial casting as a
therapeutic intervention in isolation or in
combination with other therapies (which may
include pharmacological intervention) on lower
limb dysfunction in children with CP.
2. Determine the effects of serial casting at different
points in time post cast removal.
3. Determine if the addition of pharmacological
intervention enhanced the effects of serial casting
on lower limb function.
By expanding on previous reviews as well as including
findings of recently published studies, this review may
assist clinicians and families with clinical decision-
making regarding the selection of serial casting as a pos-
sible intervention modality. For this review, passive
range of motion (PROM) of the ankle is considered the
critical outcome of interest, however, other important
outcomes impacting lower limb function will be investi-
gated, as will adverse events relating to serial casting
protocols.
Methods
Literature searches
The systematic review protocol was registered in PROS-
PERO in 2017 (Protocol Number: CRD42017077841).
The systematic literature search was initially conducted
across eight databases (PUBMED, EMBASE, CINAHL,
PEDro, OTSeeker, Cochrane, Scopus and Proquest) on
the 8th November 2017 and updated on the 25th Febru-
ary 2019. A search strategy was developed in consult-
ation with an experienced health sciences librarian
around the concepts of “Cerebral Palsy” and “serial cast-
ing”, including the use of MeSH terms, and the equiva-
lent terms on other databases. For sources which only
allowed simple searches, the key terms “Cerebral Palsy”,
“Splint*” and “Cast*” were utilized. Table 1 includes the
comprehensive search strategy.
Eligibility criteria
A comprehensive list of inclusion and exclusion criteria
is provided in Table 2. For this review, serial casting was
defined as the application or intent to apply two or more
successive fibreglass or plaster casts to a targeted joint
with efforts to increase PROM by maintaining prolonged
passive stretch in the submaximal or maximal range [21,
25–27], which may also allow for improved AROM.
Studies with an intervention that met this definition in
isolation, or in combination with other interventions
were included. However, objective outcome measures
used in clinical practice pertaining to the lower limb
were required to be provided in results for both pre-
intervention and post-intervention, or if post-
intervention scores were not reported, a change score
needed to be documented. The primary outcome meas-
ure deemed critical for this review was ankle PROM.
Other important outcomes that were justified by the
physiotherapist reviewers to be commonly used in clin-
ical practice, for measuring lower limb body function or
structures which impact activity or participation levels,
were included (e.g. hypertonicity, spasticity). Addition-
ally, direct measures of activity or participation requiring
lower limb involvement were included (i.e. functional
gait measures, gross motor skills).
Study selection
Two reviewers (EB and MM) independently ran the
search and exported results to an electronic reference
management software program, EndNote version X8
[35]. This software was used to identify duplicates and
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relevant articles, as per the PRISMA protocol [36]. As
documented in Fig. 1, studies were screened by title and
abstract, applying inclusion and exclusion criteria to
identify records that required full text for eligibility as-
sessment. Attempts were made to contact study authors
directly via email or research platforms, regarding any
data that was unclear, unpublished or unavailable in
English full text. Requests were followed up on one add-
itional occasion, after which time, if a full text version
was still unavailable, studies were not included based on
either exclusion criteria number three or four (see Table
2). Reviewers independently applied exclusion criteria to
the remaining available full text articles, documenting
reasons for exclusion. Additionally, when the same re-
search groups had published more than one article, each
reviewer independently examined the study samples and
interventions to ensure independent study samples were
being analysed. Final lists of eligible studies were com-
pared, and any discrepancies were discussed amongst
the two primary reviewers (EB and MM) and a third
reviewer (NM) was utilised to achieve consensus when
needed.
Critical appraisal of methodological quality
The methodological quality of included studies was
evaluated using the modified Downs and Black proto-
col [37], which addresses risk of bias. Two reviewers
(EB and MM) independently determined the critical
appraisal scores of each article after which, the two
reviewers met to record and discuss discrepancies.
When consensus on the appropriate score could not
be met, a third reviewer (NM) was consulted and the
consensus score was recorded. The Kennelly Rating
Scale [38] was then applied to the Downs and Black
Critical Appraisal Scores (CAS) (out of a possible
score of 28) so that the methodological quality of
each study could be determined as good (≥20 or ≥
71%), fair (15–19 or 51–70%) or poor (≤14 or ≤ 50%)
[38].
Table 1 Search Strategy
Search
#
Search Strategy Source #
Articles
1 (‘cerebral palsy’ OR (neurologic* AND condition*) OR (brain AND (injury OR injuries)) OR “Cerebral
Palsy”[Mesh]) AND (splint* OR cast* OR “Casts, Surgical”[Mesh])
Pubmed 835
2 (‘cerebral palsy’:ti,ab OR (neurologic* AND condition*):ti,ab OR (brain AND (injury OR injuries)):ti,ab OR
‘Cerebral Palsy’/exp)
AND (splint*:ti,ab OR cast*:ti,ab OR ‘Casts, Surgical’/exp)
EMBASE 888
3 (‘cerebral palsy’ OR (neurologic* AND condition*) OR (brain AND (injury OR injuries))) AND (splint* OR
cast*)
CINAHL 218
4 Cerebral palsy splint* PEDro 86
5 Cerebral palsy cast* PEDro 27
6 cerebral palsy OR (Brain AND injury) OR (Brain AND injuries) OR (Neurological AND condition) OR
(Neurological and conditions) AND splint* OR cast*
OTSeeker 39
7 (“‘cerebral palsy’”OR (neurologic* AND condition*) OR (brain AND (injury OR injuries)) OR [mh “Cerebral
Palsy”]) AND (splint* OR cast* OR [mh “Casts, Surgical”])
Cochrane (CENTRAL)
Trials only
100
8 TITLE-ABS((“cerebral palsy” OR (neurologic* AND condition*) OR (brain AND (injury OR injuries))) AND
(splint* OR cast*))
Scopus 737
9 (“cerebral palsy” OR (neurologic* AND condition*) OR CP OR (brain AND (injury OR injuries))) AND
(splint* OR cast*)
Proquest Health &
Medical Complete
289
Table 2 Eligibility criteria for screening and selection
Inclusion Criteria 1. Study must be an intervention or observational study design.
2. Study must be from a peer-reviewed journal.
3. More than 80% of participants in the intervention group must have CP (or the data for the participants with CP can be
isolated).
4. Participants must be human.
5. Participants must be children between the age of 0–18 years.
6. Participants must have undergone an intervention including serial casting of the lower limb (ankle, knee or hip).
Exclusion
Criteria
1. Studies not reporting pre- and post-casting data for outcome measures.
2. Studies published prior to 1970.
3. Studies not available in a full text version.
4. Studies not published in English or an English full text version was not obtainable.
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Data extraction and synthesis
The data collected and provided in Table S1 (Supple-
ment File 1) includes study population (age, gender, CP
classification when provided), study aims, study design,
intervention protocol, including intervention other than
serial casting. Any additional pharmacological interven-
tion (i.e. oral – e.g. baclofen, clonidine, tizanidine,
benzodiazepines, gabapentin and dantrolene or interven-
tional – e.g. BTX-A, phenol and intrathecal baclofen)
was also extracted from studies. Outcome measures used
(relevant to lower limb function), key statistical findings
including the statistical analysis performed and conclu-
sions of the publication were also reported in Table S1
(Supplement File 1). All data were extracted independ-
ently by two reviewers (EB, MM) and when discrepan-
cies existed, a third author (NM) was engaged to
independently review the data and assist with reaching
agreement on important data to extract. Finally, any
documented adverse events were recorded and reported
in the results section of this systematic review.
A meta-synthesis was conducted to explore major
trends from all included studies regarding the effects of
serial casting on the lower limb in children with CP (See
Table 3). Table 4 further syntheses of the effects of serial
casting on outcomes relevant to lower limb function in
children when the following requirements were met: i)
the study was of fair or good methodological quality; ii)
a minimum of five investigations had initially been pub-
lished using that outcome across all included studies of
fair to good methodological quality. When less than five
investigations were reported using a relevant outcome
measure, it was not included in the initial meta-synthesis
table (see Table 3).
Many clinicians consider an improvement in gait pat-
tern to be a primary aim of serial casting [39], with ankle
range of motion (PROM) and ankle angle at initial con-
tact during gait noted to be critical measures affecting
lower limb function that are commonly used in the clin-
ical setting, and consequently these kinematic measures
were included for investigation in this systematic review.
The post-casting timeframe was calculated and recorded
as the amount of time passed between the removal of
the final cast and the post-casting assessment. Within a
single study, comparisons between baseline and post-
casting measures of a reported outcome were treated as
separate investigations if the outcome data was pre-
sented at multiple post-casting timeframes. Once investi-
gations were categorized based on outcome measures
Fig. 1 Search, screening and selection process as per PRISMA protocol https://figshare.com/s/07d850b9e6873cb3f06f
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Table 3 Effects of lower limb serial casting (inclusive of additional therapeutic interventions): a meta-synthesis of findings from
individual investigations reported in fair to good methodological quality studies
Outcomes relevant to lower-
limb function.
Authors (reference no.) and Investigation Methods Relevant to the Effect of Serial
Casting
Percentage of
investigations
showing a
significant
effect from
serial casting
n/N (%)
Summary
Effect
(+,-,0,?)Significant Effect (n) Non-Significant Effect
Lower Limb Passive Range of Motion
Ankle Dorsiflexion with
Knee Flexed (KPF)
• Cameron (45) - (SC + T + A) 1mo (+)
• Cameron (45) - (SC + T + A) 4 mo (+)
• Kelly (52) - (SC + P) IP (+)
• Kelly 2018 (60) - (SC + P) IP (+)
• Kelly 2018 (60) - (SC + P) 1 mo (+)
• Kelly 2018 (60) - (SC + P) 2 mo (+)
• McNee (39) - (SC) 2-3wk (+)
• McNee (39) - (SC) 9-10wk (+)
• Corry (46) - (SC + T) 2wk (0)
• Corry (46) - (SC + T) 3mo (+)
• Kelly 2018 (60) - (SC + P) 6 mo (+)
8/11 = 72.72% (+)
Ankle Dorsiflexion
with Knee Position Extended
(KPE)
• Cameron (45) - (SC + T + A) 1mo (+)
• Cameron (45) - (SC + T + A) 4 mo (+)
• Corry (46) - (SC + T) 2wk (+)
• Kay (31) - (SC + A) 8wk (+)
• Kay (31) - (SC + P + A) 8wk (+)
• Kelly (52) - (SC + P) IP (+)
• Kelly 2018 (60) - (SC + P) IP (+)
• Kelly 2018 (60) - (SC + P) 1 mo (+)
• Kelly 2018 (60) - (SC + P) 2 mo (+)
• McNee (39) - (SC) 2-3wk (+)
• Corry (46) - (SC + T) 3mo (0)
• McNee (39) - (SC) 9-10wk (−)
• Kelly 2018 (60) - (SC + P) 6 mo (+)
10/13 =
76.92%
(+)
Ankle Dorsiflexion with
Knee Position Unspecified
(KPU)
• Boyd (15) - (SC + P + T + A) 22wk (+)
• Brouwer 1998 (44) - (SC) IP (+)
• Brouwer 1998 (44) - (SC) 6wk (+)
• Dursun (11) - (SC + P + T) IP (+)
• Dursun (11) - (SC + P + T) 9wk (+)
• Flett (22) - (SC + A) 1mo (+)
• Flett (22) - (SC + A) 3mo (+)
• Flett (22) - (SC + A) 5mo (+)
• Glanzman (16) - (SC) PE (+)
• Glanzman (16) - (SC + P) PE (+)
• Newman (53) - (Immediate serial casting
after BTXA) (SC + P + T) 3mo (+)
• Newman (53) - (Delayed serial casting
after BTXA) (SC + P + T) 3mo (+)
• Newman (53) - (Delayed serial casting
after BTXA) (SC + P + T) 6mo (+)
• Yap (58) - (SC + P + T) ~2mo (+)
• Booth (28) - (SC) 3.5 wk. (+)
• Booth (28) - (SC + P) 2 wk. (+)
• Boyd (15) - (SC + P + T + A) 10wk (+)
• Newman (53) - (Immediate serial casting
after BTXA) (SC + P + T) 6mo (+)
16/18 =
88.89%
(+)
Functional Gait
Velocity • Kelly (52) - (SC+ P) IP (−)
• Cameron (45) - (SC + T + A) 4 mo (+)
• McNee (39) - (SC) 2-3wk (+)
• McNee (39) - (SC) 9-10wk (−)
• Cameron (45) - (SC + T + A) 1mo (−)
• Kelly 2018 (60) - (SC + P) 1 mo (+)
• Kelly 2018 (60) - (SC + P) 2 mo (+)
• Kelly 2018 (60) - (SC + P) 6 mo (+)
1/8 = 12.50% (0)
Stride Length • Cameron (45) - (SC + A + T) 4 mo (+) • Cameron (45) - (SC + T + A) 1mo (+)
• McNee (39) - (SC) 2-3wk (+)
• McNee (39) - (SC) 9-10wk (+)
• Kelly (52) - (SC + P) IP (−)
1/4 = 25.00% (0)
Observational Gait Scale
(OGS)
• Dursun (11) - (SC + P + T) IP (+),
• Dursun (11) - (SC + P + T) 9wk (+)
• Newman (53) - (Immediate serial casting
after BTXA) (SC + P + T) 3mo (+)
• Newman (53) - (Delayed serial casting
after BTXA) (SC + P + T) 3mo (+)
• Newman (53) - (Delayed serial casting
after BTXA) (SC + P + T) 6mo (+)
• Newman (53) - (Immediate serial casting
after BTXA) (SC + P + T) 6mo (+)
5/6 = 83.33% (+)
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Table 3 Effects of lower limb serial casting (inclusive of additional therapeutic interventions): a meta-synthesis of findings from
individual investigations reported in fair to good methodological quality studies (Continued)
Outcomes relevant to lower-
limb function.
Authors (reference no.) and Investigation Methods Relevant to the Effect of Serial
Casting
Percentage of
investigations
showing a
significant
effect from
serial casting
n/N (%)
Summary
Effect
(+,-,0,?)Significant Effect (n) Non-Significant Effect
Physicians rating scale
(PRS) / modified PRS
• Flett (22) - (SC + A) 1mo (+) (modified
PRS)
• Flett (22) - (SC + A) 3mo (+) (modified
PRS)
• Flett (22) - (SC + A) 5mo (+) (modified
PRS)
• Yap (58) - (SC + P + T) ~2mo (+)
(modified PRS)
• Corry (46) - (SC + T) 2wks (+)
• Corry (46) - (SC + T) 3mo (+)
4/6 = 66.67% (+)
Neurological Measures
Modified Ashworth Scale
(MAS) Ankle Plantar Flexors
/ Hamstrings
• Dai (48) - (SC + P + T) IP (+)
• Dai (48) - (SC + P + T) 6wk (+)
• Dursun (11) - (SC + P + T) IP (+)
• Dursun (11) - (SC + P + T) 9wk (+)
• Flett (22) - (SC + A) 1mo (+)
• Flett (22) - (SC + A) 3mo (+)
• Flett (22) - (SC + A) 5mo (+)
• Kay (31) - (SC + A + T) 8wk (+)
• Kay (31) - (SC + A + T + P) 8wk (+)
• Kelly (52) - (SC + P) IP (+) (Ankle Plantar
Flexors)
• Kelly (52) - (SC + P) IP (+) (Hamstrings)
• Kelly 2018 (60) - (SC + P) IP (+)
• Kelly 2018 (60) - (SC + P) 1 mo (+)
• Kelly 2018 (60) - (SC + P) 2 mo (+)
• Yap (58) - (SC + P + T) ~2mo (+)
• Kelly 2018 (60) - (SC + P) 6 mo (+)
• Corry 1998 (46) - (SC + T) 2wks (+)
• Corry 1998 (46) - (SC + T) 3mo (0)
15/18 =
83.33%
(+)
Modified Tardieu Scale
(MTS)
(Ankle Plantar Flexors and
Hamstrings)
• Kelly (52) - (SC + P) IP (+) in Hamstrings
(KE)
• Newman (53) - (Immediate serial casting
after BTXA) (SC + P + T) 3mo (+) in Ankle
Plantar Flexors
• Newman (53) - (Delayed serial casting
after BTXA) (SC + P + T) 3mo (+) in Ankle
Plantar Flexors
• Newman (53) - (Delayed serial casting
after BTXA) (SC + P + T) 6mo (+) in Ankle
Plantar Flexors
• Kelly 2018 (60) - (SC + P) IP (+) DF Knee
Ext.
• Kelly 2018 (60) - (SC + P) 1 mo (+) DF
Knee Ext.
• Kelly 2018 (60) - (SC + P) 2 mo (+) DF
Knee Ext.
• Kelly (52) - (SC + P) IP (+) Ankle Plantar
Flexors with KE & KF
• Newman (53) - (Immediate serial casting
after BTXA) (SC + P + T) 6mo (+) in Ankle
Plantar Flexors
• Kelly 2018 (60) - (SC + P) 6 mo (+) DF
Knee Ext.
7/10 = 70.00% (+)
Gross Motor Function
GMFM • Dai (48) - (SC + P+ T) IP (+)
• Dai (48) - (SC + P+ T) 6wk (+)
• Kelly (52) - (SC + P) IP (+)
• Yap (58) - (SC + P + T) ~2mo (+)
• Flett (22) - Standing Dimension of GMFM
only (SC + A) 1mo (+)
• Flett (22) - Standing Dimension of GMFM
only (SC + A) 3mo (+)
• Flett (22) - Standing Dimension of GMFM
only (SC + A) 5mo (+)
• Flett (22) – Dynamic Dimension of
GMFM only (SC + A) 1mo (+)
• Flett (22) – Dynamic Dimension of
GMFM only (SC + A) 3mo (+)
• Flett (22) - Dynamic Dimension of GMFM
• Kay (31) - Dimensions C,D,E of GMFM
only (SC + A + T + P) 8wk (+)
14/15 =
93.33%
(+)
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and time points for measurement, investigations were
identified as having significant or non-significant find-
ings (see Tables 3 and 4). Two stages of coding were
undertaken. Individual investigations were coded based
on whether the effect was positive/desirable (+), nega-
tive/undesirable (−) or no effect (0). For each outcome,
the percentage of investigations reporting a significant
effect (n) were divided by the total number of investiga-
tions (N) (with fair to good methodological quality) to
determine the overall trends of serial casting on lower
limb function. The summary effect, which was the sec-
ond stage of coding, was then reported to determine the
overall effect of serial casting as either positive/desirable
(+), negative/undesirable (−) or no (0) effect. To deter-
mine a positive/desirable (+) summary effect, over 60%
of investigations needed to demonstrate a significant
positive effect. To determine a negative/undesirable (−)
summary effect, over 60% of investigations needed to
demonstrate a significant negative effect. If over 60% of
investigations demonstrated no significant effect, it was
coded as zero (0). If more than one investigation and
less than five investigations were undertaken for the ef-
fect of serial casting on any outcome or it did not meet
the above criteria, then it was coded as questionable (?)
and reported in the narrative synthesis.
Data analysis
To quantitatively address the three study aims, meta-
analyses were conducted. These analyses were completed
to assess the effect of serial casting on outcomes where a
minimum of two investigations were reported in studies
of fair to good methodological quality. Effect sizes were
calculated as mean differences (MD) or standardised
mean differences (SMD) depending on whether the data
were continuous in nature or if different scales had been
used. For each outcome assessed, variance was approxi-
mated using the standard deviation (SD) of the mean
difference (MD) between the initial measure at baseline
and the follow-up measurement. When this data was
not available the SD was calculated using the Cochrane
calculator [40] from the p-value for the differences be-
tween mean values [41]. If the p-value was not available,
the highest SD available from other included studies
using the same measure in this review was imputed
using methods previously published [42] and this was re-
quired for ten investigations during meta-analyses. Het-
erogeneity was calculated and determined using Revman
software [40]. Heterogeneity of the studies was assessed
using the I2 value from the X2 test and was determined
to be minimal when values were between 0 and 30%,
moderate when reaching 31 to 50%, substantial when
reaching 51 to 90% and considerable if over 90% [42].
Where heterogeneity was deemed to be significant,
meta-analysis was undertaken using the random-effects
model. Furthermore, the overall effects were estimated
only amongst groups of investigations that used the
same outcome variables and interventions met the pre-
defined definition of serial casting. Whilst not a defini-
tive form of assessment, graphical assessment for
publication bias was undertaken for each meta-analysis
using funnel plots as no unpublished data was available
to ascertain with more certainty if publication bias was
influencing the outcomes of each meta-analysis [43].
To address the first aim of this review, meta-analyses
were conducted to determine the pre-to-post effects of
serial casting on key outcome measures related to lower
limb function that were included in the meta-synthesis.
To address the second aim (investigating the longitu-
dinal effects of serial casting), meta-analyses were con-
ducted across four different timeframes post-completion
Table 3 Effects of lower limb serial casting (inclusive of additional therapeutic interventions): a meta-synthesis of findings from
individual investigations reported in fair to good methodological quality studies (Continued)
Outcomes relevant to lower-
limb function.
Authors (reference no.) and Investigation Methods Relevant to the Effect of Serial
Casting
Percentage of
investigations
showing a
significant
effect from
serial casting
n/N (%)
Summary
Effect
(+,-,0,?)Significant Effect (n) Non-Significant Effect
only (SC + A) 5mo (+)
• Kay (31) - Dimensions C,D,E of GMFM
only (SC + A + T) 8wk (−)
• Kelly 2018 (60) - (SC + P) 1 mo (+)
• Kelly 2018 (60) - (SC + P) 2 mo (+)
• Kelly 2018 (60) - (SC + P) 6 mo (+)
Intervention Coding: SC serial casting in isolation, + T plus allied therapies, + A = plus AFO / night splints / other orthotics, + P = plus pharmacology (which in all
instances was BTX-A)
Timeframe Coding: IP immediately post-cast removal (within 0–1 weeks); 3mo = 3months post-cast removal; 6mo = 6months post-cast removal; 12 mo = 12
months post-cast removal, (time) = 1st post-test if not immediately post, PE peak effect time not stipulated
Individual Investigation Coding: (+) = positive effect; (−) = negative effect; (0) = nil effect
Summary Coding: n/N for Outcome (%): n = number of investigations with a significant positive effect, N = total number of investigations that explore the effect of
serial casting on a given outcome. Summary Effect (+,-,0,?): (+) = ≥60% of investigations have a significant positive effect, (−) = ≥60% of investigations have a
significant negative effect, (0) = ≥60% of investigations have a non-significant effect
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of serial casting: i) Immediately post (IP), which included
studies that completed their post-treatment assessment
within seven days of final cast removal or reported only
the peak effect (i.e. one post-casting measure); ii) Short-
term (ST) > 7 days and < 3months; iii) Mid-term (MT)
between three months and > six months and; iv) Long-
Table 4 Effects of lower limb serial casting without pharmacological intervention: a meta-synthesis of findings from individual
investigations reported in fair to good methodological quality studies
Outcomes relevant to lower-limb function. Authors (reference no.) and Investigation Methods Relevant to the Effect of Serial
Casting without pharmacological intervention
Percentage of
investigations
showing a
significant
effect from
serial casting
n/N (%)
Summary
Effect
(+,-,0,?)
Significant Effect (n) Non-Significant Effect
Lower Limb Passive Range of Motion
Ankle dorsiflexion with Knee Flexed (KPF) • Cameron (45) - (SC + T + A) 1mo (+)
• Cameron (45) - (SC + T + A) 4 mo (+)
• McNee (39) - (SC) 2-3wk (+)
• McNee (39) - (SC) 9-10wk (+)
• Corry (46) - (SC + T) 2wk (0)
• Corry (46) - (SC + T) 3mo (+)
4/6 = 66.67% (+)
Ankle dorsiflexion
with knee position extended (KPE)
• Cameron (45) - (SC + T + A) 1mo (+)
• Cameron (45) - (SC + T + A) 4 mo (+)
• Corry (46) - (SC + T) 2wk (+)
• Kay (31) - (SC + A) 8wk (+)
• McNee (39) - (SC) 2-3wk (+)
• Corry (46) - (SC + T) 3mo (0)
• McNee (39) - (SC) 9-10wk (−)
5/7 = 71.43% (+)
Ankle dorsiflexion with knee position
unspecified (KPU)
• Brouwer 1998 (44) - (SC) IP (+)
• Brouwer 1998 (44) - (SC) 6wk (+)
• Flett (22) - (SC + A) 1mo (+)
• Flett (22) - (SC + A) 3mo (+)
• Flett (22) - (SC + A) 5mo (+)
• Glanzman (16) - (SC) PE (+)
• Booth (28) - (SC) 3.5 wk. (+)
7/7 = 100% (+)
Functional Gait
Velocity • Cameron (45) - (SC + T + A) 4 mo (+) • McNee (39) - (SC) 2-3wk (+)
• McNee (39) - (SC) 9-10wk (−)
• Cameron (45) - (SC + T + A)
1mo (−)
1/4 = 25.00% (?)
Stride length • Cameron (45) - (SC + A + T) 4 mo (+) • Cameron (45) - (SC + T + A)
1mo (+)
• McNee (39) - (SC) 2-3wk (+)
• McNee (39) - (SC) 9-10wk (+)
1/4 = 25.00% (?)
Physicians rating scale (PRS) / modified PRS • Flett (22) - (SC + A) 1mo (+) (modified PRS)
• Flett (22) - (SC + A) 3mo (+) (modified PRS)
• Flett (22) - (SC + A) 5mo (+) (modified PRS)
• Corry (46) (SC + T) 2wks (+)
• Corry (46) (SC + T) 3mo (+)
3/5 = 60.00% (+)
Neurological Measures
Modified Ashworth Scale (MAS) Ankle Plantar
Flexors
• Flett (22) (SC + A) 1mo (+)
• Flett (22) (SC + A) 3mo (+)
• Flett (22) (SC + A) 5mo (+)
• Kay (31) (SC + A + T) 8wk (+)
4/4 = 100.00% (?)
Gross Motor Function
GMFM • Flett (22) - Standing Dimension of GMFM only (SC +
A) 1mo (+)
• Flett (22) - Standing Dimension of GMFM only (SC +
A) 3mo (+)
• Flett (22) - Standing Dimension of GMFM only (SC +
A) 5mo (+)
• Flett (22) – Dynamic Dimension of GMFM only (SC +
A) 1mo (+)
• Flett (22) – Dynamic Dimension of GMFM only (SC +
A) 3mo (+)
• Flett (22) - Dynamic Dimension of GMFM only (SC +
A) 5mo (+)
Kay (31) - Dimensions C,D,E of GMFM only (SC + A + T)
8wk (−)
7/7 = 100% (+)
Intervention Coding: SC serial casting in isolation, + T = plus allied therapies, + A = plus AFO / night splints / other orthotics
Timeframe Coding: IP immediately post-cast removal (within 0–1 weeks); 3mo = 3months post-cast removal; 6mo = 6months post-cast removal; 12 mo = 12
months post-cast removal, (time) = 1st post-test if not immediately post, PE peak effect time not stipulated
Individual Investigation Coding: (+) = positive effect; (−) = negative effect; (0) = nil effect
Summary Coding: n/N for Outcome (%): n = number of investigations with a significant positive effect, N = total number of investigations that explore the effect of
serial casting on a given outcome. Summary Effect (+,-,0,?): (+) = ≥60% of investigations have a significant positive effect, (−) = ≥60% of investigations have a
significant negative effect, (0) = ≥60% of investigations have a non-significant effect
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term (LT) > 6 months. A final meta-analysis was
conducted addressing the third study aim; to contrast
the effects of serial casting when coupled with pharma-
cological interventions aimed at impacting spasticity,
hypertonicity or contracture (e.g. BTX-A, Baclofen),
compared to serial casting without pharmacological
intervention. For this analysis, only studies that investi-
gated the results of serial casting compared to serial
casting with pharmacological intervention were in-
cluded. Interventions may have also used additional
therapies (e.g. physiotherapy and orthoses). In addition
to the timeframe coding listed above, an additional code
has been used in the meta-analyses (Figs. 2, 3, 4, 5, 6
and 7) to document the combination of therapy inter-
ventions; i) Serial Casting (SC); ii) Pharmacological (P);
Ankle Foot Orthosis / or similar lower limb orthoses
(A); Therapy – Physical or Occupational (T).
Results
Literature search and selection
The database search identified 3219 citations, and after
removing duplicates, 1921 articles were included for
evaluation in this systematic review (see Fig. 1). After ap-
plying inclusion and exclusion criteria, 25 articles
remained [11, 15, 16, 22, 28, 29, 31, 39, 44–60]. Collect-
ively 414 children undergoing serial casting (mean age:
5.6 years) were included with 476 limbs assessed across
all studies. Two of the studies included did not have a
study population of children solely with CP. Brouwer
et al. [44] and Brouwer et al. [29] included children that
had idiopathic toe-walking; however, the pre- and post-
casting results of the children with CP were able to be
isolated for analysis. Glanzman et al. [16] included 11
participants that did not have CP; however, this was less
than 20% of the total number of participants in that
study and subsequently still met the inclusion criteria
for the present review. Figure 1 illustrates the screening
and selection process and final number of studies in-
cluded as per the PRISMA protocol [36].
Critical appraisal of methodological quality
The methodological quality score of the studies are pre-
sented in the data extraction table (see Table S1, Supple-
ment File 1). Cohen’s κ was undertaken to determine
inter-rater reliability with regards to reviewers’ judgment
on scoring individual Downs and Black items for in-
cluded studies. There was moderate agreement between
the two reviewers, κ = 0.66, p < .0001. In total, there were
differences in 17.6% of the scores for the Downs and
Black [37]. Two reviewers (EB and MM) resolved 15.8%
of the differences in scoring, and a third reviewer (NM)
assisted in resolving 1.8% of the scoring.
It was identified using the Downs and Black critical
appraisal tool that no studies represented the entire
source population (i.e. all children diagnosed with CP)
from which they were recruited (item #11) and to the
same manner, no subjects who participated, represented
the entire population from which they were recruited
(item #12). Nine studies were deemed to have poor
methodological quality [29, 47, 50, 51, 54–57, 59], eleven
studies were deemed to have fair methodological quality
[15, 16, 22, 28, 39, 44–46, 49, 53, 58] and five studies
were found to have good methodological quality [11, 31,
48, 52, 60]. When critically appraising the internal valid-
ity of studies, items relevant to the recruitment period of
participants (item #22), blinding to randomized assign-
ment (item #24) and adjustment for confounding vari-
ables (item #25) were all major contributors impacting
the methodological quality studies included in this sys-
tematic review. Furthermore, a lack of power analysis
was noted in most of studies with only 20.0% of studies
reporting power (item #27). All articles scored ‘0’ for
item #14 and only six (25%) articles scored ‘1’ for item
#15. These two questions were related to blinding sub-
jects and blinding the individuals measuring the out-
comes respectively, and this contributed to the reduced
overall internal validity of the studies included in this
systematic review. Additionally, there were many studies
that did not report losses to follow up, further impacting
the quality rating scores of those studies. See Table S1
(Supplement File 1) for a detailed summary of all studies
included in this review and their critical appraisal scores.
Although sixteen studies with fair to good methodo-
logical quality explored the effects of serial casting on
lower limb function, results from a number of investiga-
tions included in Table S1 did not meet the pre-defined
criteria of a minimum of five investigations from fair to
good methodological studies, and for this reason were
not included in the meta-synthesis (Tables 3 and 4). Ef-
fects of serial casting on particular outcomes were not
included in meta-synthesis when the associated studies
did not meet the threshold for methodological quality or
when the required number of investigations for a par-
ticular outcome to be included was not met, and conse-
quently the outcome measures that were not included in
meta-synthesis comprised multiple body structure or
function measures as well as activity and participation
level outcomes. The body structure and function mea-
sures that were not included in meta-synthesis were:
knee extension PROM [50, 52, 55, 56], hip abduction
PROM [51], Thomas Test [51], knee PROM (popliteal
angle) [50, 51], ankle dorsiflexion AROM [58], knee ex-
tension AROM [56], ankle angle at initial foot contact
[46, 49], Modified Ashworth Scale (MAS) assessing the
hamstrings [52, 56], Ashworth Scale (not modified) [46],
velocity of passive stretch [29, 44], Tardieu Scale (not
modified) [11], Modified Tardieu Scale R1 angle ankle
DF [54], dynamic assessment of ROM (DROM) [50],
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reflex excitability [29, 44], isometric plantar flexion (PF)
strength [44] and Physiological Cost Index (PCI) [45].
Activity or participation level measures that were not in-
cluded were: gait velocity [45], gait-related cadence [39,
52], WeeFim mobility scale [58], the Berg Balance Test
[56] and Paediatric Evaluation of Disability Inventory
(PEDI) [52]. The remaining measures included for meta-
synthesis have been grouped according to clinical utility
themes and are presented as: i) Lower Limb Range of
Motion; ii) Functional Gait Measures; iii) Neurological
Assessments and; iv) Gross Motor Function.
Populations and interventions identified in studies with
fair to good methodological quality
The 16 studies with fair to good methodological quality
had relatively small study cohorts, ranging from nine to 80
participants, with a mean of 28 participants per study.
Four hundred and forty participants undergoing serial
casting were included across these studies. The age of par-
ticipants ranged from two to 14 years with a mean age of
5.9 years. The materials used, and the positioning and
handling of patients was varied across studies. Two studies
[15, 46] did not state their casting protocol with enough
detail to replicate in future studies, six studies reported
the use of fiberglass [28, 31, 39, 52, 53, 60], while two re-
ported using Plaster of Paris (POP) casting materials [15,
48]. Two studies [52, 60] published protocols to specify
patient positioning in supine during application of casting,
while five other studies reported positioning in prone [16,
28, 39, 45, 53]. Six studies specified that the knee was
flexed to 90 degrees [16, 29, 39, 52, 53, 60] during the ap-
plication of casting and four reported that the sub-talar
joint was positioned into neutral with the forefoot aligned
to the hind-foot [29, 45, 52, 60]. A plaster boot or walking
shoe was provided for subjects in seven studies [31, 39, 45,
52, 53, 58, 60]. Serial casting duration and frequency were
also varied across the 16 fair to good studies. Casts were
applied for durations varying between 72 h to four weeks
and between one to four casts were used across the serial
casting protocols. All studies intended to use two or more
Fig. 3 a Effects of serial casting on gait for children with Cerebral Palsy. https://figshare.com/s/bb37fa42c86e569fbca6 b. Funnel plots for effects
of serial casting on gait for children with Cerebral Palsy https://figshare.com/s/9bb27a5ca3ca5896db55
(See figure on previous page.)Fig. 2 a Effects of serial casting on ankle dorsi-flexion for children with Cerebral Palsy. https://figshare.com/s/
89970dbb9ab5ac3eb71a b Funnel plots for effects of serial casting on ankle dorsi-flexion passive range of motion for children with Cerebral Palsy
https://figshare.com/s/5d1117d9b927018c0a41
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casts during the protocol if required. Assessment time-
frames for all reported outcome measures ranged widely
from immediately post-completion of serial casting
through to more than 12months post-final cast removal.
Thirteen of the studies with fair to good methodological
quality explored the use of BTX-A as a pharmacological
intervention to improve outcomes relevant to lower limb
structure, function or activity [11, 15, 16, 22, 28, 31, 46,
48, 49, 52, 53, 58, 60]. Whilst this review intended to re-
port the outcomes of studies using any additional pharma-
cological intervention to address spasticity, when coupled
with serial casting, no pharmacological intervention, other
than BTX-A, was explored in the included studies with
fair to good methodological quality. For this reason, the
remainder of the results will refer to BTX-A when appro-
priate for reporting on pharmacological interventions.
Aims 1 and 2: overall and longitudinal effectiveness of
serial casting as a therapeutic intervention in isolation or
in combination with other therapies (which may include
pharmacological intervention)
The primary outcomes that met the threshold for inclu-
sion in the meta-synthesis were relevant to: i) Lower limb
range of motion; ii) Functional gait; iii) Neurological
Fig. 4 a Effects of serial casting on hypertonicity (MAS) for children with Cerebral Palsy. https://figshare.com/s/f92823032da7d3fed181 b Funnel
plots for effects of serial casting on hypertonicity (MAS) for children with Cerebral Palsy https://figshare.com/s/5faa9f389d0dedfd67b8
Fig. 5 Effects of serial casting on spasticity for children with Cerebral Palsy with funnel plot https://figshare.com/s/d33f8e096262c8eab7fc
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measures and; iv) Gross motor function (see Tables 3 and
4). The results from studies with fair to good methodo-
logical quality are narratively synthesized below.
Lower limb range of motion
Fourteen out of the sixteen studies of fair to good meth-
odological quality reported the effects of serial casting
on PROM at the ankle [11, 15, 16, 22, 28, 31, 39, 44–46,
52, 53, 58, 60], at both baseline and post-casting inter-
vention. Within these 14 studies, there were 42
individual investigations exploring the effects of serial
casting on lower limb PROM. For ankle DF PROM,
there were 18 investigations [11, 15, 16, 22, 28, 44, 53,
58] where the knee position was unspecified (KPU), 11
investigations [39, 45, 46, 52, 60] where the knee pos-
ition flexed (KPF) and 13 investigations [31, 39, 45, 46,
52, 60] with the knee position extended (KPE) during as-
sessment. The summary coding for the meta-synthesis
(see Tables 3 and 4) revealed an overall positive/desir-
able effect when using serial casting to improve ankle
Fig. 6 a Effects of serial casting on gross motor function for children with Cerebral Palsy. https://figshare.com/s/b88afff7075e75191432 b Funnel
plots for effects of serial casting on gross motor function for children with Cerebral Palsy https://figshare.com/s/112d0557375f01d43b4b
Fig. 7 Effects of Serial Casting on Ankle Dorsi Flexion Range of Motion with versus without pharmacological intervention for children with
Cerebral Palsy with funnel plot https://figshare.com/s/68959259873dad102b61
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DF PROM in children with CP. This desirable effect was
maintained when investigations using BTX-A were re-
moved (see Table 4).
The results of a meta-analysis of multiple investigations
across 11 studies [11, 16, 22, 31, 39, 44–46, 53, 58, 60] with
fair to good methodological quality that reported ankle DF
PROM outcomes are presented in Fig. 2a. Studies were
grouped according to knee position: flexed (KPF), extended
(KPE), or unspecified (KPU). Three articles measuring this
outcome were not included in the meta-analysis as they did
not report baseline data [15, 28, 52]. The overall combined
results demonstrated substantial heterogeneity (77%) when
the studies were inclusive of pharmacological intervention,
which in all cases was BTX-A and when meta-analysis was
independent of pharmacological intervention substantial
heterogeneity remained (81%), consequently, it was not ap-
propriate to calculate a pooled effect estimate to assess the
overall effect of serial casting on ankle DF PROM (see Fig.
2a). Additionally, funnel plots represented in Fig. 2b suggest
that publication bias may be present for studies investigat-
ing the effects of serial casting on ankle DF PROM with
KPE, although publication bias cannot be confirmed due to
the high levels of heterogeneity across the studies. However,
serial casting was shown via meta-analysis to significantly
improve Ankle DF PROM when the knee position was un-
specified (KPU) in the immediate (IP) and short term (ST)
(independent of pharmacological intervention) and in the
mid-term (MT) (inclusive of pharmacological intervention
– which in all cases was BTX-A) (see Table 5). When the
knee position was flexed during measurement (KPF), serial
casting had a significant desirable effect on Ankle DF
PROM in the mid-term (MT) with BTX-A included and
without pharmacological intervention (see Table 5). There
were no investigations exploring the effects of serial casting
on DF PROM at long-term follow up beyond 6months.
Functional gait measures
Ten studies of fair to good methodological quality re-
ported data on one or more of the following outcomes re-
lated to functional gait: velocity [39, 45, 52, 60], stride
length [39, 45, 52, 60], Observational Gait Scale (OGS)
[11, 53] and the Physician’s Rating Scale (PRS) [22, 46,
58]. Meta-syntheses revealed that serial casting (inclusive
of additional therapeutic interventions) had no significant
effect on velocity and stride length (see Table 3). The ef-
fect of serial casting (without pharmacological interven-
tion) on velocity or stride length was questionable (see
Table 4) due to the minimum number of investigations
not meeting the threshold for meta-synthesis. Results of
the meta-synthesis suggest that serial casting (both with
BTX-A and without pharmacological intervention) results
in a desirable outcome on functional gait when measured
with the Physicians Rating Scale (PRS). There were insuffi-
cient studies reporting cadence or ankle angle at initial
contact to undertake a meta-synthesis or meta-analysis.
Results from a meta-analysis comparing baseline and
post-casting data for Observational Gait Scale (OGS) and
PRS were presented together as objective standardized gait
measures, and are reported in Fig. 3a, demonstrating that
serial casting (inclusive of additional therapeutic interven-
tions) has an overall positive effect on functional gait and
although slightly less effective the positive effect remained
when studies using additional pharmacological interven-
tion were removed from the analysis (see Fig. 3a). Funnel
plots in Fig. 3b, revealed that publication bias did not im-
pact these results. Stride length and velocity were not in-
cluded in the meta-analysis as their summary coding from
the meta-synthesis demonstrated a non-significant effect
from serial casting (see Table 3).
When exploring the longitudinal effects of serial casting
on functional gait the results of meta-analyses identified a
positive significant effect of serial casting (inclusive of add-
itional therapeutic interventions) in the short and mid-term
timeframes. These effects remained positive in the mid-
term but not in the short term when studies using add-
itional pharmacological intervention (which in all cases was
BTX-A) were removed from the analysis (see Table 5).
Minimal heterogeneity was noted across the studies. There
were insufficient data to explore, via meta-analyses, the im-
mediate post effects of serial casting on functional gait out-
comes. Based on two investigations from one study [53],
serial casting (inclusive of additional therapeutic interven-
tions) did not appear to have a significant long-term effect
on functional gait outcomes (see Table 5).
Neurological assessments
Eight studies of fair to good methodological quality re-
ported data from neurological assessment measures in-
cluding: The Ashworth/Modified Ashworth Scale (MAS)
assessing hypertonicity in both hamstring [52] and ankle
plantar-flexor muscle groups [11, 22, 31, 46, 48, 52, 58,
60], the Tardieu/Modified Tardieu Scale (MTS) indicat-
ing R1 (spastic catch) angle for knee extension [52], or
R2-R1 difference (spasticity) for ankle plantar-flexors
[52, 53, 60]. There were sufficient investigations to de-
termine the effect of serial casting on only two neuro-
logical outcomes via meta-synthesis. These were the
MAS for ankle plantar-flexors (n/N = 82.35%), and MTS
(R1, R2-R1) (n/N = 70.00%), suggesting a desirable effect
of serial casting (inclusive of additional therapeutic inter-
ventions) for reducing hypertonicity (see Table 3) and a
questionable effect of serial casting for reducing (MAS)
when interventions were not inclusive of pharmaco-
logical input (due to a limited number of investigations
– see Table 4). A meta-analysis was conducted with
studies that measured the effects of serial casting on
hypertonicity using the MAS. The overall combined re-
sults inclusive of pharmacological intervention (which in
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Table 5 Longitudinal and Collective Effects of Serial Casting on the Lower Limb for Children with Cerebral Palsy
Outcome / Measure Effect of Serial Casting
Inclusive of additional therapeutic interventions Studies with pharmacological intervention (in all
cases this was BTX-A) were removed from meta-
analyses
Ankle DF KPU Timelines Studies Mean
difference
(MD or
*SMD)
Confidence
Interval
Hetero-
geneity
Test for
Overall
Effect
Z Score
(p-value)
Studies Mean
difference
(MD or
*SMD)
Confidence
Interval
Hetero-
geneity
Test for
Overall
Effect
Z Score
(p-value)
IP 44, 11,
22, 16
15.15 [11.74,
18.56]
I2 =
66%
NC 44, 16 12.51 [11.10,
13.92]
I2 = 0% Z = 17.35
(p <
0.00001)
ST 44, 11,
22, 58
8.74 [5.76, 11.73] I2 =
51%
NC 44, 22 6.84 [5.25, 8.43] I2 = 0% Z = 8.43
(p <
0.00001)
MT 22, 53 8.54 [5.78, 11.31] I2 = 0% Z = 6.06
(p <
0.00001)
22 8.47 [3.69, 13.25] I2 = 0% Z = 3.47
(p =
0.0005)
LT 53 6.29 [2.23, 10.35] I2 = 0% Z = 3.03
(p =
0.002)
– – – – –
Ankle DF KPF IP – – – – – – – – – –
ST 45,46,
60, 39
6.50 [3.21, 9.79] I2 =
61%
NC 45, 46,
39
6.31 [0.84, 11.79] I2 =
76%
NC
MT – – – – – 45, 46 5.92 [1.76, 10.08] I2 = 0% Z = 2.79
(p =
0.005)
LT – – – – – – – – – –
Ankle DF KPE IP – – – – – – – – – –
ST 45, 46,
31, 60,
39
7.42 [3.44, 11.40] I2 =
82%
NC 45, 46,
31, 39
6.05 [0.93, 11.18] I2 =
80%
NC
MT 45, 46 3.14 [−3.24, 9.51] I2 =
71%
NC 45, 46 3.14 [−3.24, 9.51] I2 =
71%
NC
LT – – – – – – – – – –
Functional Gait
(Objective
Standardised
Measures)
IP – – – – – – – – – –
ST 46, 11,
22
* 0.83 [0.43, 1.23] I2 = 0% Z = 4.11
(p <
0.0001)
46, 22 * 0.58 [−0.06, 1.22] I2 = 0% Z = 1.79
(p = 0.07)
MT 46, 22,
53
* 0.88 [0.41, 1.36] I2 =
16%
Z = 3.63
(p =
0.0003)
46, 22 * 0.59 [0.07, 1.11] I2 = 0% Z = 2.24
(p = 0.03)
LT – – – – – – – – – –
Neuro – Hypertonicity
(MAS) PF
IP 48, 11,
60
* -2.13 [−4.43, 0.18] I2 =
96%
NC – – – – –
ST 46, 48,
11, 22,
31, 60
* -1.37 [−1.97,
−0.77]
I2 =
79%
NC 46, 22,
31
* -1.24 [−1.73,
−0.76]
I2 = 0% Z = 5.01
(p <
0.00001)
MT – – – – – 46, 22 * -0.49 [− 1.02,
0.03]
I2 = 0% Z = 1.86
(p = 0.06)
LT – – – – – – – – – –
Neuro – Spasticity
(MTS) (R2-R1)
IP – – – – – – – – – –
ST 60 * -1.61 [−2.35, −
0.88]
I2 = 0% Z = 4.30
(p <
0.0001)
– – – – –
MT 53 * -2.46 [−5.71, 0.79] I2 = NC – – – – –
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all cases was BTX-A) demonstrated substantial hetero-
geneity (85%) across the studies, consequently, it was
not appropriate to calculate a pooled effect estimate (see
Fig. 4a). However, when meta-analysis was undertaken
independent of studies using pharmacological interven-
tion the overall effect of serial casting on hypertonicity
of the ankle plantar flexors was shown to be significantly
desirable (see Fig. 4a) and this significant desirable effect
occurs mostly in the short term (ST) (see Table 5). The
funnel plot for the meta-analysis in Fig. 4b, revealed that
there was no evidence of publication bias impacting the
results when studies using pharmacological interventions
were removed. There was no data to examine the effects
of serial casting on hypertonicity in the long term.
A meta-analysis was also conducted with studies that
measured the effects of serial casting (inclusive of add-
itional therapeutic interventions) on spasticity using the
MTS. The overall combined results inclusive of BTX-A
demonstrated substantial heterogeneity (74%) across the
studies, consequently, it was not appropriate to calculate
a pooled effect estimate (see Fig. 5) and publication bias
could not be accurately assessed. When meta-analyses
were undertaken to explore the effects of serial casting
on spasticity, a small but significant effect was demon-
strated in the short-term (ST) when BTX-A injections to
the gastrocnemius were included in the protocol (see
Table 5) however this was not maintained in the mid
(MT) or long-term (LT). Insufficient data was available
to undertake a meta-analysis to examine the effects of
serial casting on lower limb spasticity independent of
pharmacological intervention.
Gross motor function
Six studies [22, 31, 48, 52, 58, 60] of fair to good
methodological quality reported the effects of lower
limb serial casting on gross motor proficiency, using
the Gross Motor Function Measure (GMFM). The
meta-synthesis (Table 3) revealed that serial casting of
the lower limb (inclusive of additional therapeutic in-
terventions) had an overall desirable effect on gross
motor function and this desirable effect remained
when investigations inclusive of pharmacological
intervention were not included. However, results from
a meta-analysis comparing baseline to post-casting
GMFM scores (inclusive of additional therapeutic in-
terventions) demonstrated considerable heterogeneity
(95%) across the studies, consequently, it was not ap-
propriate to calculate a pooled effect estimate (see
Fig. 6a) and publication bias could not be accurately
assessed from the funnel plots (see Fig. 6b). When
studies including pharmacological interventions
(which in all cases was BTX-A) were removed from
the meta-analysis results showed that serial casting
did not have a significant effect on gross motor func-
tion (GMFM) (see Fig. 6a). When exploring the longi-
tudinal effects of lower limb serial casting
(independent of pharmacological intervention) on
gross motor proficiency, meta-analyses revealed no
significant changes in GMFM scores between baseline
and follow-up in the short-term (ST) and mid-term
(MT), post serial casting (see Table 5). There were
insufficient published investigations to determine the
immediate effects of serial casting on gross motor
Table 5 Longitudinal and Collective Effects of Serial Casting on the Lower Limb for Children with Cerebral Palsy (Continued)
Outcome / Measure Effect of Serial Casting
Inclusive of additional therapeutic interventions Studies with pharmacological intervention (in all
cases this was BTX-A) were removed from meta-
analyses
90%
LT 60, 53 * -1.31 [−3.09, 0.47] I2 =
87%
NC – – – – –
GMFM IP – – – – – – – – – –
ST 48, 22,
31, 60,
58
5.49 [−6.46,
17.45]
I2 =
95%
NC 22, 31 0.80 [−9.47,
11.08]
I2 = 0% Z = 0.15
(p = 0.88)
MT – – – – – 22 8.03 [−4.71,
20.76]
I2 = 0% Z = 1.23
(p = 0.22)
LT – – – – – – – – – –
IP Immediately post serial casting (within 7 days of final cast removal), ST Short-term post serial casting (> 7 days and < 3months), MT Mid-term post serial casting
(between 3months and < 6months), LT Long-term post serial casting (> 6months)
Ankle DF (Dorsi Flexion) KPU (Knee Position Unspecified), KPF (Knee Position Flexed), KPE (Knee Position Extended). GMFM (Gross Motor Function Measure)
MD Mean Difference, *SMD Standardised Mean Difference (used when outcome is not measured in consistent units or with consistent tools)
Significance value for Test of Overall Effect (Z) set at p < 0.05
NC Not calculated (when heterogeneity I2 was either substantial (50–90%) or considerable (> 90%) the pooled effect estimate was not calculated
– represents insufficient data to undertake the meta-analysis
Note: where one study is listed individually, a minimum of two investigations from that study were utilised for the meta-analysis
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function and there were no studies that explored the
long-term effects of serial casting on gross motor
function for children with CP (see Table 5).
Aim 3: determining if the addition of pharmacological
intervention enhances the effects of serial casting
Only three studies [16, 28, 31] assessed the effects of ser-
ial casting (SC ± A ± T) compared to the effects of serial
casting in combination with pharmacological interven-
tion (SC ± P ± A ± T). The pharmacological intervention
in all three studies was identified as BTX-A. One study
was shown to have good methodological quality [31] and
two had fair methodological quality [16, 28]. From these
studies, the only common outcome measure was ankle
DF PROM which was collectively measured with knee in
an extended (KPE), or unspecified (KPU) position. Fig-
ure 7 demonstrates a small but positive overall effect
favouring serial casting with the addition of BTX-A by
just over three degrees. Heterogeneity was considered
minimal suggesting the three studies were similar in
terms of their findings and publication bias did not ap-
pear to be impacting the results, however the small
number of studies limit the accuracy of using funnel
plots to make this assessment. As the study by Booth
et al. [28] provided the average change per week rather
than the absolute pre-post casting change in DF PROM,
a sensitivity analysis was undertaken to explore the effect
of serial casting when this study [28] was removed. The
results of the sensitivity analysis showed the results were
slightly modified (MD − 2.62 degrees; 95% CI − 6.46 to
1.22; P = 0.18; I2 - = 0%) and whilst the addition of BTX-
A still achieved greater ankle DF PROM, the difference
between the two intervention methods became non-
significant when the study by Booth (2003) was
removed.
Adverse events from intervention
All adverse events from interventions (when reported)
were documented in Table S1. Supplement File 1 (Data
Extraction Table). Adverse events documented when
BTX-A was utilised across all studies included: Calf pain
(n = 3), with Dai (2007) [48] documenting ‘most patients’
suffered from calf pain; Excessive weakness (n = 1); In-
creased micturition and faecal soiling for 1-month post
injection (n = 1) and three studies [11, 16, 22] stated that
no patients displayed adverse events when their protocol
included BTX-A. Adverse events noted in studies utilis-
ing serial casting (independent of pharmacological inter-
vention) across all studies included: Foot pain (n = 4);
Calf pain (n = 2); Skin inflammation (n = 3); Pressure
sores – grade 1–2 (n = 5) and; Lower limb atrophy (n =
3). A small number of concerns were also noted with
dissatisfaction with the procedure of serial casting (n =
3) and difficulty with home-care bathing (n = 4) were
also noted across the studies collectively. Adverse events
from utilising combined BTX-A and casting were noted
in two studies and included: Lower limb weakness (n =
12); Pain (n = 3); Lower limb atrophy (n = 12); Tempor-
ary incontinence (n = 3); Constipation (n = 1); Pressure
sores (n = 1) and; Tendonitis (n = 1). Nine of the in-
cluded studies [28, 39, 44, 45, 50, 54, 56–58] did not re-
port adverse effects of the intervention in their
manuscripts and a further four studies [29, 31, 52, 60]
stated that there were ‘not adverse events’ during their
interventions.
Discussion
The overall objective of this systematic review was to
identify the efficacy of serial casting as an intervention in
the management of lower limb dysfunction in children
with Cerebral Palsy. Other systematic reviews have ad-
dressed the utility of serial casting as an adjunct to
pharmacological intervention [32, 33] or are now consid-
ered to be out of date [17, 21, 25]. No recent publica-
tions have summarized findings solely according to
higher methodological quality studies to determine the
effect of serial casting on lower limb function, nor have
recent publications provided a meta-analysis of findings
relevant to the study aims to allow more robust conclu-
sions. The results of this systematic review with meta-
analyses suggest that serial casting (independent of
BTX-A) can have significant desirable effects on i) in-
creasing ankle DF PROM in the immediate (IP) to mid-
term (MT); ii) reducing hypertonicity in the short-term
(ST) and; iii) improving functional gait in the mid-term
(MT). Furthermore, the findings of this review indicate
that the effects of serial casting on ankle DF PROM are
further and significantly enhanced by the combination of
BTX-A, however the clinical significance of the magni-
tude of this effect remains unclear. These findings sup-
port the use of serial casting in clinical practice to
manage impairments at the body function and structure
level to improve lower limb activities such as gait.
Relevant to the first aim, the strongest findings were in
the immediate (IP) and short-term (ST) periods post
casting, when the knee position was unspecified (KPU)
for DF PROM measurement, which made it difficult to
differentiate the most implicated muscles involved in the
overall effect. However, serial casting appeared to have
the strongest effect on the soleus muscles of the triceps-
surae three to six months after serial casting. This may
be the result of the gastrocnemius muscles shortening
quicker than the soleus muscles after earlier gains from
serial casting. However, in order to truly understand
what components of casting are causing the most effect-
ive outcomes, it is recommended that future studies in-
clude more detailed reporting of their casting protocols
(i.e. casting duration and position, subject positioning,
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weight bearing status, casting material, as well as adjunct
therapy before, during and after serial casting) and meas-
urement protocols, to enable better identification of pos-
sible contributors for the effects of serial casting. For
example, if a below-knee cast is applied, with the intent
to lengthen the gastrocnemius, one may clinically reason
that the footplate of the cast needs to end distal to the
first toe, with the footplate of the cast having a flat sole,
without the addition of an inserted rocker, and that a
regular exercise program utilising full knee extension in
standing and walking activities should be prescribed. If
the details of the casting protocol were consistently de-
scribed, it may be possible for future reviews to identify
which components are having the most effect on the
studied outcomes.
When used in clinical practice, the main aim of serial
casting is to increase PROM around the ankle to eventu-
ally achieve adequate AROM at the ankle to reach heel
strike at first foot contact, to consequently improve
functional gait parameters and other age-specific func-
tional outcomes. Data synthesis (see Tables 3 and 4),
identified that serial casting overall did not have a sig-
nificant effect on walking velocity or stride length. How-
ever, it is important to note that for walking velocity,
only two studies reported significant effects, one of
which [52] claimed that that serial casting had a signifi-
cant undesirable effect on walking velocity and stride
length immediately post-cast removal (one week after
final cast removal). However, statistical results were not
reported for stride length and this study used serial cast-
ing after BTX-A injections. This undesirable effect is
most likely attributed to the weakening impact of BTX-
A and the negative implications that prolonged
immobilization has on muscular strength, and this hy-
pothesis is supported by the increased adverse effects for
children when serial casting and BTX-A were combined.
This negative effect has been described previously in the
empirical literature [61], where ankle plantar-flexion
torque, fatigue resistance and functional recovery follow-
ing casting for ankle fracture were examined. Reduced
ability to generate plantar-flexor muscle force has direct
implications during the late stages of stance phase,
which can ultimately influence stride length and gait vel-
ocity [62]. This undesirable effect indicates a need for
intermittent serial casting with lower limb strengthening
incorporated in-between cast applications, as opposed to
continuous casts over prolonged periods. The recom-
mendations by Novak and colleagues in 2013 [17], re-
garding lower limb strength training and electrical
muscle stimulation, appear critical for enhancing a
child’s strength and therefore function, post- and per-
haps during serial casting episodes, especially when
using prolonged serial casting protocols. Most studies
with intermittent casting protocols were excluded from
this systematic review as they failed to meet our pre-
determined definition of serial casting. Results pertaining
to muscle strength post-casting were not reported in this
review as there were not sufficient studies investigating
this outcome in the included literature. Further investi-
gation into the effects of combining serial casting with
brief (e.g. 1–2 days) non-casting periods of age-
appropriate strengthening activities is therefore
warranted.
Another desirable effect of serial casting identified in
this review was the reduced influence of hypertonicity
on muscles around the ankle joint, in the short-term
(ST) post-cast removal. The authors of this review feel
that these benefits may have translated into the improve-
ment in functional gait described in some studies [22,
53], with improved ankle DF PROM allowing for im-
proved clearance of the foot in the mid-swing phase of a
limb implicated with hypertonicity. Important to ad-
dressing the aims of this study, functional gait improve-
ments (using objective standardised measures) were
observed in studies that used serial casting without
pharmacological intervention (see Table 4) although
meta-analyses did not demonstrate a carry-over effect
with gross motor skills as significant changes in gross
motor function measure scores were not observed. An
improved ability to reach heel strike may have accounted
for improved balance, which is reflected in the improved
functional gait outcomes reported in this review. The
decrease in hypertonicity in the lower limb post-casting
reported in studies assessing hypertonicity using the
MAS [11, 22, 31, 48, 52, 58] may also have positively im-
pacted functional gait for similar reasons. Whilst the
MAS is a commonly used measure in clinical practice,
future research could use more objective measures (e.g.
electromyography) to quantify the responses of serial
casting on hypertonicity levels, which may allow for
more definite assessments of the relationship between
decreased levels of hypertonicity and improved gait and
/ or gross motor outcomes.
In addressing the second aim of this review; the effects
of serial casting longitudinally, the authors identified that
there were no fair or good quality studies investigating
the long-term effects of serial casting (i.e. greater than
six months) independent of pharmacological interven-
tion, on lower limb function for ankle DF PROM, hyper-
tonicity (MAS), spasticity (MTS), gait (OGS) or gross
motor function (GMFM). It is therefore recommended
that future longitudinal studies are conducted to deter-
mine the efficacy and sustainability of serial casting as
an intervention for long-term management of lower limb
dysfunction in children with CP. The findings from fu-
ture longitudinal studies, particularly if compared to
long-term effects of additional pharmacological interven-
tions, would further assist parents/carers in their
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decision-making regarding preferred methods of inter-
vention. These options should then be discussed with
children and their carers using shared decision-making
models for treatment planning [63].
The findings related to the third aim of this review
suggest that the addition of pharmacological interven-
tion to serial casting results in slightly yet significantly
better ankle DF PROM; however, these findings should
be interpreted with caution. An additional two-to-three
degrees of ankle DF PROM may translate to be func-
tionally beneficial if the ankle DF range of an individual
is within a few (two to three) degrees of achieving neu-
tral ankle DF. However, this may not be functionally
beneficial if the individual has either i) already achieved
neutral ankle DF, or, ii) is substantially greater than
three degrees away from achieving neutral ankle DF
from an originally plantarflexed position. During human
gait, critical foot clearance is influenced by slight move-
ments at the ankle joint. A study undertaken by Moo-
sabhoy and colleagues in 2006 [64], suggested that the
point of critical toe clearance occurs when the ankle is
slightly dorsiflexed (at approximately one degree past
neutral). Therefore, if the addition of two-to-three de-
grees ankle DF from the pharmacological intervention
(i.e. BTX-A) achieves range through the point of critical
toe clearance, then it is likely to be of clinical value
above and beyond serial casting alone. Importantly, our
sensitivity analysis showed that the difference in DF
PROM between serial casting and serial casting with
pharmacological intervention (which in all cases was
BTX-A) became non-significant when one study [28]
that used alternative measurement options was removed
from the meta-analysis. This suggests that the findings
rest on limited data and further high quality randomized
controlled trials exploring the differences between serial
casting and serial casting with BTX-A or other pharma-
cological interventions are needed. Further, only one of
the three studies clearly identified the knee position as
being extended during measurement of ankle PROM
and whilst the other two studies implied that the knee
was extended, implicating the effect in the gastrocne-
mius muscles, there was a lack of clarity from authors of
the included studies for reporting the measurement pro-
tocols. In view of our findings, it is important for clini-
cians to take into consideration that certain
pharmacological interventions such as BTX-A are neu-
rotoxins and whilst medically controlled they are consid-
ered safe for use with children, however, are generally
more invasive with potentially higher risks [65]. Conse-
quently, it is imperative that clinical reasoning and spe-
cific goal-setting related to lower limb function is
incorporated in the family-centered decision-making
process prior to recommending the addition of BTX-A
to serial casting, on the basis that it is likely to result in
only slightly better ankle DF PROM (see Fig. 7) with po-
tentially more adverse effects.
In undertaking this systematic review, the authors
identified several limitations in the published empirical
literature. Many of the articles included had poor meth-
odological quality, which was commonly attributed to a
lack of detailed reporting of either the methods and/or
results of the study. For example, many studies failed to
report actual probability values, did not use appropriate
statistics, or did not report statistical tools used. Several
studies used the ANOVA statistical method of analysis
without reporting a post-hoc analysis, preventing the
identification of the point of significant difference from
baseline to each post-treatment measure. This lack of
detailed reporting also limited the ability to include such
studies in the meta-analyses for this systematic review.
Consequently, the authors of the present review needed
to use estimation calculations or to exclude data from
meta-analyses, which limited the ability to draw firm
conclusions regarding the aims of this review and may
have contributed to the substantial heterogeneity ob-
served in many of the meta-analyses. In future research,
it is recommended that authors report all statistics thor-
oughly, particularly mean values with standard devia-
tions for transparency of findings and or publish their
complete set of de-identified data. This will enable more
sound analyses to be made in future systematic reviews
and consequently firmer conclusions can be made.
The inconsistency of the data from the variety of as-
sessment methods and outcome measures used, made it
difficult to synthesize and quantify the magnitude of the
reported serial casting effects. Additionally, the method
of cast application was varied and on many occasions
was not reported at all, making it challenging to analyze
and quantify the potential impact of different serial cast-
ing protocols on lower limb function. Factors such as
the duration of serial casting, the goal of serial casting,
materials utilized, and different combinations of adjunct
therapy varied immensely across the included studies
and were also likely contributors to the large degree of
heterogeneity, commonly prohibiting pooled effect esti-
mates being calculated. The authors of this review rec-
ommend that future research relevant to this topic
consider using casting protocols that are already preva-
lent in the literature or report their methodology in a
detailed manner which would permit replication of
methods, to allow the effects of serial casting to be thor-
oughly explored in future systematic reviews. The au-
thors of this review acknowledge that to do this, journal
publishers need to allow for extended word counts in
presenting the methods of studies undertaken. Further-
more, this review revealed large degrees of heterogeneity
for a number of analyses, and this was mostly related to
the inconsistency of casting protocols, age populations
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and GMFCS classifications. Blackmore and colleagues in
2007 [21], reported a similar issue, stating that studies in
their review had small sample sizes and lacked
randomization and blinding, making it challenging to
identify the true effects of serial casting as an interven-
tion. To reduce the impact of these limitations, future
studies should report detailed assessment and interven-
tion protocols and procedures. Additionally, randomized
controlled trials contrasting the effects of serial casting
versus serial casting with BTX-A or other pharmaco-
logical interventions would also be useful for therapists
to assist with clinical decision-making.
A number of limitations exist in this systematic review.
The first limitation was the authors’ inability to collect
all full text and/or English versions of relevant studies.
Some studies were inaccessible in English language and
some abstracts were not yet published in full text form.
As a result, there may have been relevant studies that
were not included in this review. Another potential limi-
tation of this review was the author’s decision to exclude
studies if they included participants outside of childhood
age range (0 to 18 years). This resulted in data on chil-
dren within the accepted age range being excluded as it
could not be dissected from adult populations. Although
attempts were made to extract raw data pertaining to
participants aged 0 to 18 years, if relevant data could not
be isolated in the publication, the study was excluded
altogether. Further, inclusion of studies with participants
ranging from 0 to 18 years may limit the translation of
findings to specific more refined age populations within
this range. Publication of de-identified data sets (as is
now being requested by many journals) may have been
useful for addressing this limitation. The authors deci-
sion to record the effects of serial casting across multiple
timeframes and introduce these into the meta-analyses
was undertaken to enhance the effect size and opportun-
ity for a conclusive result, however this created signifi-
cant heterogenous samples for some analyses, suggesting
a large degree of dissimilarity in the individual study re-
sults. To account for the significant heterogeneity, a ran-
dom effects model was used when appropriate to assess
both intra-study sampling errors and between-study
variation, resulting in wider confidence intervals and
more conservative findings. A different methodological
approach to data synthesis and analysis may have led to
even stronger findings when examining the effects of
serial casting on each of the outcome measures.
Despite the above-mentioned limitations, there are
also many strengths to the present review. The method-
ology conducted was thorough and comprehensive with
two to three reviewers involved at every stage, ensuring
the reliability of the results from this study. Additionally,
this systematic review provided a meta-analytic approach
to addressing the study aims whenever possible, which
was not done in previously published systematic reviews
or overviews investigating the same or similar topics.
Another strength of this review was the authors’ decision
to ensure quality of the results being synthesised by only
including fair to good quality studies for meta-synthesis,
and only analyzing outcomes if there was a minimum of
five investigations for the meta-synthesis and a mini-
mum of two investigations for meta-analysis. Although a
consequence of these methods meant that some data
relevant to the effects of serial casting were omitted
from analysis and thus from the overall findings of the
review, it ensured that the results presented, and conclu-
sions drawn were from accumulated trustworthy
sources. The major strength of this review was that it
drew conclusions from a detailed meta-synthesis and
further quantified findings of previous reviews by includ-
ing a meta-analysis using data from the stronger meth-
odological quality studies only, when it was possible. No
previous systematic review exploring the effects of serial
casting on lower limb function in children with CP has
previously undertaken a meta-analysis to form conclu-
sions, except for Kelly and colleagues who published a
Cochrane protocol in 2008 [25], however this systematic
review was withdrawn from publication in 2017 due to
being out of date. Since the beginning of 2008, there
have been six additional relevant papers added to the
empirical literature that were included in our review.
More recently Novak and colleagues in 2013 [17], pub-
lished a broad systematic review supporting the use of
serial casting to improve joint range in the lower limbs,
however no findings were published in this review re-
garding the effects of serial casting on functional gait.
Therefore, we feel that the present review provides new
insights into the functional benefits of serial casting in-
dependent of BTX-A.
Conclusions
Findings from this systematic review suggest that serial
casting is effective for increasing passive ankle DF
PROM and decreasing hypertonicity in the lower limbs.
Additionally, the findings of this review suggest that ser-
ial casting coupled with BTX-A in children with CP has
a slightly more but significantly favorable effect on ankle
DF PROM. Further high-quality research is required to
investigate the effects of serial casting with and without
pharmacological interventions on other functional lower
limb outcomes. Overall, the results of this systematic re-
view support the clinical use of serial casting of the
lower limb for improving functional outcomes (i.e. gait
via increased ankle DF) in children with CP and suggest
that the effects on ankle DF PROM may be slightly
stronger when coupled with BTX-A. These findings
however, need to be balanced against recent research
which showed that small improvements in ankle DF
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achieved from BTX-A injections to the gastrocnemius
(without the addition of serial casting) were offset by po-
tentially harmful effects of deteriorating knee kinematics,
moving children with spastic diplegia CP towards crouch
gait patterns [34]. Clinicians may use the information
gained from the present systematic review when devel-
oping individualized treatment plans for children who
have CP during shared decision-making consultations
clients and their families. Further research investigating
the longitudinal effects of serial casting using clearly
documented casting protocols and assessment proce-
dures would be valuable to clinicians and researchers.
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